Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 25, 2026

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

Predictive modelling in hormone-refractory prostate cancer (HRPC).

J Bellmunt1, J Carles, J Albanell

  • 1Department of Medical Oncology, University Hospital del Mar-IMIM, Barcelona, Spain. jbellmunt@imas.imim.es

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|February 13, 2009
PubMed
Summary

Predictive models can aid treatment decisions for hormone-refractory prostate cancer (HRPC). A new model uses PSA kinetics and clinical factors to predict survival in metastatic HRPC patients receiving chemotherapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in patients with high body mass index or diabetes mellitus.

ESMO open·2026
Same author

Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors.

ESMO open·2025
Same author

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.

ESMO open·2025
Same author

Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial.

ESMO open·2024
Same author

Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments.

ESMO open·2024

Area of Science:

  • Oncology
  • Prostate Cancer Research

Background:

  • Hormone-refractory prostate cancer (HRPC) treatment decisions are challenging due to limited evidence.
  • Prognostic models are crucial for stratifying patients and informing treatment choices.

Purpose of the Study:

  • To develop and validate a multivariate prognostic model for predicting survival in metastatic HRPC.
  • To incorporate PSA kinetics and novel clinical factors for improved predictive accuracy.

Main Methods:

  • Utilized data from a phase III randomized trial of docetaxel in metastatic HRPC patients.
  • Developed a multivariate model incorporating PSA kinetics (PSA-DT) and clinical variables like pain, disease progression type, liver metastases, and metastatic site count.

Main Results:

Related Experiment Videos

Last Updated: Jun 25, 2026

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence
08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

  • The novel model accurately predicts 1, 2, and 5-year survival in metastatic HRPC patients.
  • Identified baseline pain, type of progression, liver metastases, and number of metastatic sites as independent prognostic factors.

Conclusions:

  • The developed nomogram is a valuable tool for stratifying patients in clinical trials involving docetaxel-based therapies.
  • This model can help delineate the potential benefits of chemotherapy in HRPC management.